Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 OCF Margin % is 22.90% as of Jun. 2026, which is 2% below its 10-year median of 23.25. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 90.2% on this metric.
The historical rank and industry rank for Medpace Holdings's OCF Margin % or its related term are showing as below:
FRA:01P'
s OCF Margin % Range Over the Past 10 Years
Min: 21.76 Med: 23.25 Max: 28.87
Current: 27.01
During the past 13 years, the highest OCF Margin % of Medpace Holdings was 28.87%. The lowest was 21.76%. And the median was 23.25%.
FRA:01P's OCF Margin % is ranked better than 90.2% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs FRA:01P: 27.01
Medpace Holdings OCF Margin % Related Terms
Medpace Holdings OCF Margin % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:01P vs ICLR, RVTY, CRL: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (FRA:01P) has a OCF Margin % of 22.90% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medpace Holdings and its competitors. This is near median its historical median of 23.25. Over the past decade, Medpace Holdings' OCF Margin % has ranged from 21.76 to 28.87. According to the industry distribution chart, Medpace Holdings ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 9.8%.
Is Medpace Holdings' OCF Margin % too high?
Medpace Holdings' current OCF Margin % of 22.90% is near median its 10-year median of 23.25. Over the past 10 years, this metric has ranged from a low of 21.76 to a high of 28.87. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. Medpace Holdings' value of 22.90% is 381.6% above this industry median. Based on the distribution chart, Medpace Holdings ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' OCF Margin % compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #20 out of 204 companies for OCF Margin %. This places Medpace Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.76. Medpace Holdings' value of 22.90% is 381.6% above this benchmark. Historically, Medpace Holdings' own OCF Margin % has ranged from 21.76 to 28.87 over the past decade. While the company's 10-year median is 23.25 vs. the industry median of 4.76, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current OCF Margin % of 22.90% is 381.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current OCF Margin % is 22.90%, which is near median its own 10-year median of 23.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current OCF Margin % is 22.90%, which is near median its 10-year median of 23.25 and 381.6% above the Medical Diagnostics & Research industry median of 4.76. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current OCF Margin % is 22.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
OCF Margin %: 22.90% (near median its 10-year median of 23.25)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
Industry Position: 381.6% above the Medical Diagnostics & Research median (#20 of 204)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
